Breaking News: Pasha Brands Supports Federal Petition Requesting a Reassessment of the Medical Cannabis Program and Exemptions for Unlicensed Compassion Clubs and Medical Dispensaries | Financial Buzz

Breaking News: Pasha Brands Supports Federal Petition Requesting a Reassessment of the Medical Cannabis Program and Exemptions for Unlicensed Compassion Clubs and Medical Dispensaries

Pasha Brands Ltd. (CSE: CRFT) (OTC: CRFTF), Canada’s largest craft cannabis brand house, last month called for the complete expungements of cannabis records, and a review of post-legalization enforcement. In the wake of raids on the nation’s oldest compassion clubs and dispensaries, Pasha is now calling on the federal government to look into new models of medical access.

As legal adult-use is clearly failing to meet the needs of the same cannabis patients being left behind by the medical access program, and as an association of legal cannabis producers calls on the federal government to increase enforcement on brick and mortar and online illicit retailers, Pasha calls on the federal government to instead exempt Canada’s earliest medical dispensaries, it’s patients, and it’s producers from the Cannabis Act, and to conduct a review of the current medical framework.

Several court cases have set precedents in Canada that have been largely ignored by successive governments. The right to access medical cannabis has been well-established by the courts, but this access is lacking.  Not all patients who require cannabinoid-based medicine have access to online sales, fixed addresses, credit cards, or the funds required to purchase their medicine. For these reason and others, the recommendations following both R. v. Smith and Allard v. Canada touted the benefits of storefront access at dispensaries and compassion clubs.

What’s more, access to medical cannabis is protected under Section 7 of the Charter of Rights and Freedoms. This access is also meant to include ‘protection from delay’. The 2002 Report of the Senate Special Committee on Illegal Drugs found that medical dispensary practices were in line with therapeutic indications, and that moving forward, Health Canada should work with compassion clubs, rather than against them. By the Senate’s own recommendations, these outlets should be part of Canada’s existing medical cannabis framework.

Pasha supports this petition calling on the federal government to take action on these now 17-year-old recommendations by supporting and encouraging the development of new models of access; to undertake a full review of the current state of medical cannabis access while including the organizations that inspired and impressed the Senate Committee in 2002; and to grant exemptions to medicinal dispensaries, their patients, and suppliers as the review is ongoing.

Pasha has focused on getting existing farmers into the legal adult-use market, but recognizes the need for improved medical access. “The pre- and post-legalization gold rush on both licit, and illicit, sides of the industry has skewed our understanding of what it means to safely access cannabis,” says Jamie Shaw, Pasha’s Chief Communications and Culture Officer. “The current framework fails patients, and without proper medical access, they are forced to purchase their medicine from the illicit market or go without. We hope that by gaining MP support for this petition, the public will get a chance to remind the federal government that it was medical patients that carved the path that we’re on today, and it is they who still bear the brunt of bad policy.”

The petition (e-2301) can be read here:

and has been filed with the House of Commons, and currently awaits MP support.

About Pasha Brands

Based in Vancouver, British Columbia, Pasha is a vertically integrated, prohibition-era brand house firmly rooted in BC’s craft cannabis industry, which boasts an international reputation. With proven capabilities in cannabis cultivation, genetic research and development, product processing, and retail, Pasha is uniquely positioned in the new legal cannabis market through its network of hundreds of craft cannabis suppliers under the Pasha umbrella.

Pasha subsidiary, Medcann Health Products Ltd., is a Health Canada licensed cultivator and processor with a licence to sell medical cannabis products in Canada.

Pasha, and its subsidiary BC Craft Supply, are also developing a craft cannabis campus, which is dedicated to bringing craft quality into the newly legal cannabis market in Canada. BC Craft is driven to assist craft growers in obtaining security clearance and licensing to grow as micro-cultivators, specializing in education and compliance to bring growers into the regulated cannabis supply market.

Sponsored Content Release. Click for Full Disclosure

  • Sponsored Content Release, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For pasha brands ltd. financial and corporate news dissemination, has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: